Reports and Briefs

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Report
Report

Beyond The Blockbuster Drug

The blockbuster model now delivers just 5% ROI: competitive pressures and falling R&D productivity will instigate a new pharmaceutical model that replaces the unsustainable blockbuster model - personalized medicine and the “nichebuster”.

Published By Business Insights
08 Feb 2005 $2875
Buy
Report
Report

The Biogenerics Market Outlook

The absence of generic competition has meant that growth of branded generics has gone unchallenged. But by 2010, biologic medicines worth $11.2bn in sales annually are expected to lose patent protection in developed pharmaceutical markets.

Published By Business Insights
16 Mar 2005 $2875
Buy
Report
Report

The Future of Array Technologies

DNA microarrays have changed the study of genetics by enabling the screening of whole genomes within a single microarray. Recent developments offer real potential in many applications from point-of-care diagnostics to high throughput lab devices.

Published By Business Insights
16 Jun 2005 $2875
Buy
Report
Report

Pharmaceutical Project and Portfolio Management

Pharma companies operate in multi-project, multi-product environments. The challenge facing executives is to decide which projects - each may have a strong value proposition and be championed by different business units - should receive investment.

Published By Business Insights
23 Jun 2005 $2875
Buy
Report
Report

Drug Safety in the Post-Vioxx Era

Although Vioxx is the most severe safety scare to date, similar problems could occur again given the commercial availability of various products that have been linked to widespread severe reactions and the lack of sufficient regulatory controls.

Published By Business Insights
14 Jul 2005 $2875
Buy
Report
Report

Myelodysplastic Syndrome: An Underserved Population Offers Commercial Opportunity

SuperGen/MGI Pharma's Dacogen and Celgene's Revlimid are in pre-registration for treatment of myelodysplastic syndrome (MDS). However, a significant proportion of the MDS population will be left underserved by pharmacotherapy.

Published By Datamonitor
18 Oct 2005 $1900
Buy
Report
Report

The Eastern European Cardiovascular Market Outlook to 2010

This report provides comprehensive coverage of the major cardiovascular markets in the Eastern European region, and offers detailed analysis of market trends, epidemiology, current leading brands of treatment, product sales forecast and future market leaders over the period 2005–2010 in 12 regional markets, including Poland, Hungary, Lithuania, the Czech Rep, and Russia.

Published By Business Insights
03 Jan 2006 $2875
Buy
Report
Report

The Latin American Cardiovascular Market Outlook to 2010

This report provides comprehensive coverage of the major cardiovascular markets in the Latin American region, and offers detailed analysis of market trends, epidemiology, current leading brands of treatment, product sales forecast and future market leaders over the period 2005–2010 in 10 markets: Brazil, Mexico, Argentina, Puerto Rico, Chile, Venezuela, Colombia, Ecuador, Peru, Uruguay.

Published By Business Insights
06 Jan 2006 $2875
Buy
Report
Report

The Asian Cardiovascular Market Outlook to 2010

This report provides comprehensive coverage of the major cardiovascular markets in the Asia Pacific region, and offers detailed analysis of market trends, epidemiology, current leading brands of treatment, product sales forecast and future market leaders over the period 2005–2010 in nine markets: China, India, Singapore, South Korea, Thailand, Philippines, Malaysia, Indonesia and Taiwan.

Published By Business Insights
12 Jan 2006 $2875
Buy
Report
Report

Pharmaceutical Branding Strategies: Thought leader perspectives on brand building, effective communication and future brand models

This report provides a unique insight into the best practices of leaders at the forefront of shaping pharmaceutical industry branding, and offers expert analysis on key branding issues and their impact on DTC marketing, PR, corporate communications and Rx to OTC switching, and also forecasts future brand models.

Published By Business Insights
25 Jan 2006 $2875
Buy

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.